Optimized 2'-Deoxyadenosine Api Intermediate Synthesis Route for Industrial Scale
[Reaction Yield Optimization]: Advanced chemical reduction protocols achieve over 98% step yield without chromatographic separation.
[Supply Chain Resilience]: Secure tonnage quantities of API Intermediate with stable lead times for global antiviral production.
[Quality Verification]: Every batch includes full impurity profiling and HPLC data to ensure Pharmaceutical Grade compliance.
As a critical building block in the development of antiviral and anticancer therapeutics, 2'-Deoxyadenosine (CAS: 958-09-8) represents a high-value API Intermediate within the nucleoside analog market. Its role as a structural fragment of DNA makes it essential for genetic medicine and the synthesis of modified nucleosides such as cladribine and ddA. For process chemists and procurement officers, selecting a manufacturer capable of delivering consistent Industrial Purity while maintaining cost-effective Bulk Price structures is paramount. At NINGBO INNO PHARMCHEM CO.,LTD., we specialize in scalable manufacturing processes that meet the rigorous demands of modern pharmaceutical supply chains.
Biocatalytic Production Methods
Enzymatic transglycosylation remains a viable Synthesis Route for specific stereoisomers of deoxyribonucleosides. This biocatalytic approach typically utilizes enzymes such as E. coli purine nucleoside phosphorylase (PNP) and thymidine phosphorylase (TP) in a Tris-HCl buffer system. While this method offers high stereoselectivity under mild conditions (pH 7.5, room temperature), it often presents challenges regarding enzyme stability and downstream purification at the tonnage scale. The reaction mixture requires careful filtration through specialized membranes and vacuum concentration to isolate the product from by-products like 7-methylguanine.
For large-scale industrial applications, reliance solely on biocatalysis can limit throughput due to the cost of enzyme immobilization and batch-to-batch variability. Consequently, many commercial manufacturers hybridize these methods or opt for fully chemical synthesis to ensure supply stability. When sourcing high-purity 2'-Deoxyadenosine, buyers should evaluate whether the production method aligns with their specific impurity profile requirements for downstream coupling reactions.
Chemical Synthesis Pathways
Chemical synthesis from adenosine offers a robust alternative for generating Desoxyadenosine derivatives with superior scalability. A preferred industrial protocol involves a three-step sequence: esterification, acylation, and reduction. This route avoids the use of toxic heavy metal salts often found in older methodologies, such as mercury chloride condensation.
Step 1: Regioselective Esterification
The process initiates with adenosine reacting with a dialkyltin oxide esterifying agent in methanol or dichloromethane at 75–80°C. This step forms a stannylene acetal intermediate, which protects the 2' and 3' hydroxyl groups. The use of dialkyltin oxide enhances reaction selectivity, ensuring that subsequent acylation occurs primarily at the 2'-position.
Step 2: Acylation and Activation
Following esterification, the intermediate undergoes acylation using p-toluenesulfonyl chloride in the presence of an organic base like triethylamine. This converts the 2'-hydroxyl into a good leaving group (tosylate) without requiring intermediate purification, thereby reducing solvent waste and processing time.
Step 3: Reduction and Purification
The final step involves reduction using a hydride-ion-transfer reducing agent, such as lithium triethylborohydride in anhydrous THF or DMSO. This deoxygenation step proceeds under inert gas shielding to prevent oxidation. Modern optimized protocols achieve total recovery rates exceeding 77% with final HPLC purity greater than 99.0%. The crude product is purified via recrystallization in ethanol, eliminating the need for costly column chromatography.
| Parameter | Specification | Test Method |
|---|---|---|
| CAS Number | 958-09-8 | N/A |
| Chemical Name | 2'-Deoxyadenosine / Adenine Deoxyribose | IUPAC |
| Purity (HPLC) | ≥ 99.0% | Area Normalization |
| Appearance | White to Off-White Crystalline Powder | Visual |
| Loss on Drying | ≤ 0.5% | Karl Fischer / LOD |
| Heavy Metals | ≤ 10 ppm | ICP-MS |
| Residual Solvents | Compliant with ICH Q3C | GC Headspace |
Scalability for API Intermediate
Transitioning from laboratory synthesis to commercial production requires strict adherence to GMP Standard guidelines and regulatory compliance such as REACH and TSCA. Executives must consider not only the chemical feasibility but also the supply chain security of raw materials like adenosine and reducing agents. NINGBO INNO PHARMCHEM CO.,LTD. maintains a vertically integrated supply chain to mitigate risks associated with raw material scarcity.
Our manufacturing facilities are equipped to handle tonnage quantities, ensuring that clinical trial materials can be seamlessly scaled to commercial launch volumes without re-validating the Manufacturing Process. We understand that consistency is key for regulatory filings; therefore, our batch records include detailed impurity profiles and spectral data (NMR, MS) to support drug master files (DMF).
For procurement teams evaluating vendors, it is critical to request a batch-specific COA to verify parameters such as optical rotation and specific impurities related to the reduction step. We invite you to contact our technical sales team for a batch-specific COA, SDS, or bulk pricing quote to support your upcoming production cycles.